Vertex Pharmaceuticals (XTER:VX1) Cash Flow from Discontinued Operations : €0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Vertex Pharmaceuticals's cash flow from discontinued operations for the three months ended in Mar. 2025 was €0 Mil. It means Vertex Pharmaceuticals received €0 Mil from the sale of part of business quarterly. Vertex Pharmaceuticals's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2025 was €0 Mil.

Vertex Pharmaceuticals Cash Flow from Discontinued Operations Historical Data

The historical data trend for Vertex Pharmaceuticals's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cash Flow from Discontinued Operations Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

Vertex Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

Vertex Pharmaceuticals Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Vertex Pharmaceuticals Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (XTER:VX1) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy 0QZU:UK VRTX34:Brazil VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines